

FDA & UNIVERSITY OF MARYLAND CERSI

# PHARMACOKINETIC EVALUATION IN PREGNANCY VIRTUAL PUBLIC WORKSHOP

Monday, May 16, 2022 & Tuesday, May 17, 2022

*Engaging stakeholders in dialogue to assess available science and data gaps to advance the conduct of PK studies in pregnant individuals for CDER-regulated products.*

May 16 10:00am – 3:00pm (ET)

## *Day 1 – Welcome & Introduction*

- 10:00 – 10:10 Welcome & Introductory remarks  
*Leyla Sahin, FDA*
- Keynote Address  
*Robert Califf, Commissioner of Food and Drugs*

## *Session 1: Considerations for Conduct of PK Studies in Pregnant Individuals*

Introduction of Speakers – *Daphne Guinn*

- 10:10 – 10:25 General landscape of existing regulatory guidance and drug labeling in pregnancy  
*Leyla Sahin, FDA*
- 10:25 – 10:40 Ethical considerations for enrolling pregnant individuals in clinical studies  
*Anne Lyerly, University of North Carolina*
- 10:40 – 11:00 Physiologic changes during pregnancy and impact on drug disposition and response  
*Ahizechukwu Eke, John Hopkins University*
- 11:00 – 11:15 PK studies in pregnancy – Regulatory experience  
*Su-Young Choi, FDA*
- 11:15 – 11:30 Public health perspective on PK studies in pregnancy  
*Martina Penazzato, WHO-IMPAACT*
- 11:30 – 11:45 The conundrum of clinical studies in pregnancy: Industry view  
*Michael Fossler, Cytel*
- 11:45 – 11:55 Q&A – *Morning speakers*

11:55 – 12:15	BREAK
12:15 – 12:35	Design considerations for pharmacokinetic studies in pregnant individuals <i>Mary Hebert, University of Washington</i>
12:35 – 12:55	Designing PK Studies in Pregnancy – Part II <i>Catherine Stika, Northwestern University</i>
12:55 – 1:10	Importance of achieving racial and ethnic equity in pregnancy clinical research <i>Adetola Louis-Jacques, University of Florida</i>
1:10 – 1:20	Q&A – <i>Afternoon speakers</i>
1:20 – 2:50	Panel Discussion  <i>Moderators</i> – Lynne Yao, FDA & Solange Corriol-Rohou, AstraZeneca  <i>Panelists</i> – <ul style="list-style-type: none"> <li>▪ Yodit Belew, FDA</li> <li>▪ Christina Bucci-Rechtweg, Novartis</li> <li>▪ Maged Costantine, Ohio State University</li> <li>▪ Melanie Kerr, Patient Representative</li> <li>▪ Aaron Pawlyk, NIH/NICHD</li> <li>▪ Raman Venkataramanan, University of Pittsburgh</li> </ul>
2:50 – 3:00	Closing Remarks <i>Elimika Pfuma Fletcher, FDA</i>

---

## May 17 10:00am – 2:00pm (ET)

Introduction of Speakers – CAPT *Anissa Davis-Williams*

### *Day 2 – Welcome & Introduction*

10:00 – 10:10	Welcome & Introductory remarks <i>Elimika Pfuma Fletcher, FDA</i>
---------------	--

### *Session 2: Modeling Pregnancy Pharmacokinetics*

10:10 – 10:25	Overview of current modeling approaches to support studies in pregnancy <i>Jeff Barrett, Critical Path</i>
10:25 – 10:40	The role of modelling and trial design considerations – regulatory perspective <i>Susan Cole, MHRA</i>
10:40 – 10:55	Industry perspective on role of PBPK modeling in pregnancy <i>Amy Cheung, Certara</i>
10:55 – 11:10	Predicting maternal-fetal exposure to drugs using a mechanistic PBPK model <i>Jashvant Unadkat, University of Washington</i>

- 11:10 – 11:20 Q&A – *Session 2 Speakers*
- 11:20 – 12:10 Panel Discussion  
*Moderator* – Elimika Pfuma Fletcher, FDA  
**Panelists** –
- Karim Azer, Axcella
  - Gil Burckart, FDA
  - Andre Dallmann, Bayer
  - Manuela Grimstein, FDA
  - Sara Quinney, Indiana University

12:10 – 12:25 BREAK

### *Session 3: Data Interpretation & Translation into Dosing Recommendations in Pregnancy*

- 12:25 – 12:40 Innovative data analytics to inform pharmacokinetics and dosing of drugs in pregnancy  
*Mathangi Gopalakrishnan, University of Maryland*
- 12:40 – 12:55 Translating data into dosing recommendations in pregnancy  
*Brookie Best, University of California San Diego*
- 12:55 – 1:05 Q&A – *Session 3 Speakers*
- 1:05 – 1:50 Panel Discussion  
*Moderators* – Elimika Pfuma Fletcher, FDA & Sara Quinney, Indiana University  
**Panelists** –
- Edmund Capparelli, University of California San Diego
  - Steve Caritis, University of Pittsburgh
  - Kellie Reynolds, FDA
  - Ashley Strougo, Sanofi
  - Kimberly Struble, FDA
- 1:50 – 2:00 Closing Remarks & Future Directions  
*Lynne Yao*  
*Director, Division of Pediatrics and Maternal Health, Office of New Drugs, CDER*

---

#### Additional information

This workshop is open to the public; however, registration is required at:  
<https://bioeumd.wufoo.com/forms/modi0au1wjs8as/>.

More information about this event can be found at: <https://go.usa.gov/xu2MX>